Scarica l'app Stockscreener
12.60
1.12%
0.14
Dopo l'orario di chiusura:
12.63
0.03
+0.24%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$12.46
Aprire:
$12.39
Volume 24 ore:
9.55M
Relative Volume:
1.15
Capitalizzazione di mercato:
$14.51B
Reddito:
$14.33B
Utile/perdita netta:
$-3.79B
Rapporto P/E:
-3.9748
EPS:
-3.17
Flusso di cassa netto:
$1.84B
1 W Prestazione:
+1.20%
1M Prestazione:
+13.62%
6M Prestazione:
+36.07%
1 anno Prestazione:
+5.35%
Intervallo 1D:
$12.37
$12.72
Intervallo di 1 settimana:
$12.19
$12.72
Portata 52W:
$6.85
$12.72
Viatris Inc Stock (VTRS) Company Profile
Nome
Viatris Inc
Settore
Telefono
(724) 514-1465
Indirizzo
1000 MYLAN BOULEVARD, CANONSBURG
Confronta VTRS con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
VTRS
Viatris Inc
|
12.60 | 14.35B | 14.33B | -3.79B | 1.84B | -3.17 |
|
ZTS
Zoetis Inc
|
126.85 | 55.38B | 9.40B | 2.65B | 2.24B | 5.935 |
|
TAK
Takeda Pharmaceutical Co Adr
|
16.37 | 50.23B | 29.63B | 260.53M | 5.51B | 0.0788 |
|
HLN
Haleon Plc Adr
|
10.04 | 44.75B | 14.26B | 1.98B | 2.47B | 0.4327 |
|
TEVA
Teva Pharmaceutical Industries Ltd Adr
|
32.51 | 37.17B | 16.88B | 666.71M | 251.19M | 0.6132 |
|
UTHR
United Therapeutics Corp
|
490.83 | 21.69B | 3.08B | 1.24B | 1.07B | 25.61 |
Viatris Inc Stock (VTRS) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-12-09 | Iniziato | Barclays | Overweight |
| 2025-10-15 | Iniziato | Truist | Buy |
| 2025-06-06 | Iniziato | Goldman | Neutral |
| 2024-07-19 | Ripresa | Jefferies | Buy |
| 2023-10-23 | Downgrade | BofA Securities | Neutral → Underperform |
| 2023-06-23 | Downgrade | Barclays | Equal Weight → Underweight |
| 2023-04-24 | Downgrade | Barclays | Overweight → Equal Weight |
| 2023-02-17 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2023-01-27 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-11-10 | Aggiornamento | UBS | Sell → Neutral |
| 2022-11-08 | Aggiornamento | Piper Sandler | Underweight → Neutral |
| 2022-10-21 | Ripresa | Jefferies | Hold |
| 2022-06-14 | Iniziato | UBS | Sell |
| 2022-05-10 | Downgrade | Piper Sandler | Neutral → Underweight |
| 2022-03-01 | Downgrade | BofA Securities | Buy → Neutral |
| 2022-03-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-06-15 | Iniziato | Citigroup | Neutral |
| 2021-04-07 | Ripresa | RBC Capital Mkts | Outperform |
| 2021-03-08 | Downgrade | Goldman | Buy → Neutral |
| 2021-03-02 | Downgrade | JP Morgan | Overweight → Neutral |
| 2021-02-26 | Downgrade | Wolfe Research | Outperform → Peer Perform |
| 2021-01-05 | Iniziato | Argus | Hold |
| 2020-12-14 | Iniziato | Bernstein | Mkt Perform |
Mostra tutto
Viatris Inc Borsa (VTRS) Ultime notizie
Why Viatris Inc. stock remains on buy listsMarket Activity Report & Safe Entry Zone Identification - ulpravda.ru
Viatris stock hits 52-week high at 12.68 USD By Investing.com - Investing.com South Africa
Viatris appoints Lara Ramsburg as chief people and corporate affairs officer - MarketScreener
Viatris names Lara Ramsburg as chief people and corporate affairs officer - Investing.com Australia
Viatris names Lara Ramsburg as chief people and corporate affairs officer By Investing.com - Investing.com South Africa
Viatris Appoints Lara Ramsburg as Chief People and Corporate Affairs Officer - Viatris
Viatris Inc.: How a Quiet Generic Drug Giant Is Re?wiring Global Healthcare - AD HOC NEWS
Barclays initiates Viatris (VTRS) with overweight as pharma sentiment improves - MSN
Is Viatris stock outperforming the Dow? - MSN
Viatris (VTRS) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
Taxanes Market to Reach US$ 8.67 Billion by 2032 at 10.73% CAGR; - openPR.com
1 Healthcare Stock to Target This Week and 2 We Turn Down - FinancialContent
A Look At Viatris (VTRS) Valuation After Recent Regulatory And Pipeline Milestones - Yahoo Finance
Anti-Depression Drugs Market to Reach USD 22.10 Billion by 2031 | - openPR.com
Viatris Inc.: Can a Hybrid Pharma Powerhouse Redefine Global Generics and Biosimilars? - AD HOC NEWS
Take Profit: Will Viatris Inc stock outperform Nasdaq indexJuly 2025 Setups & Verified Chart Pattern Signals - moha.gov.vn
Viatris Inc. (VTRS) Provides Updates on Four Recent Regulatory Milestones - Finviz
Viatris Inc (VTRS)'s Uncertain Future: Understanding the Barriers to Outperformance - GuruFocus
Viatris stock hits 52-week high at $12.60 By Investing.com - Investing.com Nigeria
Viatris stock hits 52-week high at $12.60 - Investing.com India
Viatris Inc. stock rises Wednesday, outperforms market - MSN
Barclays Initiates Viatris (VTRS) with Overweight as Pharma Sentiment Improves - Insider Monkey
Viatris Inc. stock rises Tuesday, outperforms market - MarketWatch
Viatris Inc. (VTRS) Stock Analysis: Navigating a 3.90% Dividend Yield Amidst Challenging Metrics - DirectorsTalk Interviews
Viatris Inc. Stock Climbs 1.8%, Outperforms Market - 富途牛牛
Prescription for Growth: Why Zoetis and Viatris are Defining Healthcare’s New Winners in 2025 - FinancialContent
How Is The Market Feeling About Viatris Inc?Viatris (NASDAQ:VTRS) - Benzinga
Viatris: Looks Cheap, But Faces Continued Contraction (NASDAQ:VTRS) - Seeking Alpha
Wall Street Recap: How strong is Viatris Inc. stock revenue growthStock Surge & Safe Capital Growth Trade Ideas - moha.gov.vn
Earnings Risk: How Viatris Inc. (VIA) stock trades after earningsPortfolio Gains Summary & AI Powered Buy and Sell Recommendations - ulpravda.ru
Is Viatris’ Shift Into Complex Therapies Altering The Investment Case For VTRS? - Yahoo Finance
Viatris (VTRS): Reassessing Valuation After Recent Share Price Gains and Evolving Investor Sentiment - Yahoo Finance
Opus Genetics Partner Files Supplemental NDA for Presbyopia Drug - TipRanks
Viatris Gets FDA Nod for Generic Sandostatin, Shares Regulatory Updates - Yahoo News Malaysia
Is Viatris Inc. stock safe for conservative investorsEarnings Miss & Fast Moving Stock Watchlists - DonanımHaber
Viatris’ MR-146 gains IND clearance for neurotrophic keratopathy - BioWorld MedTech
Viatris secures four regulatory milestones across global pipeline By Investing.com - Investing.com Australia
Will Viatris Inc. stock outperform Nasdaq index2025 Valuation Update & Verified Technical Trade Signals - DonanımHaber
Viatris Provides Pipeline Update on Four Regulatory Milestones - The Malaysian Reserve
Update Recap: How Viatris Inc. stock valuations compare to rivalsWeekly Market Report & Fast Entry Momentum Alerts - Улправда
Chemotherapy Induced Anemia Market Intelligence Report 2025-2032, Featuring Amgen, Johnson & Johnson - PharmiWeb.com
Viatris racks up regulatory wins across therapy areas - The Pharma Letter
Viatris Says FDA Approves Octreotide Acetate, Clears MR-146 for Clinical Trials - marketscreener.com
Rally Mode: How Viatris Inc VIA stock behaves in tightening cyclesQuarterly Portfolio Summary & Scalable Portfolio Growth Methods - moha.gov.vn
Viatris secures four regulatory milestones across global pipeline - Investing.com
Viatris provides pipeline update on four regulatory milestones - marketscreener.com
Viatris Provides Pipeline Update On Four Regulatory Milestones - TradingView — Track All Markets
Viatris Inc Azioni (VTRS) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.59%
1.75%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):